These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26413747)

  • 21. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
    Lastere S; Dalban C; Collin G; Descamps D; Girard PM; Clavel F; Costagliola D; Brun-Vezinet F;
    Antivir Ther; 2004 Apr; 9(2):221-7. PubMed ID: 15134184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accumulation of P(T/S)AP late domain duplications in HIV type 1 subtypes B, C, and F derived from individuals failing ARV therapy and ARV drug-naive patients.
    Martins AN; Arruda MB; Pires AF; Tanuri A; Brindeiro RM
    AIDS Res Hum Retroviruses; 2011 Jun; 27(6):687-92. PubMed ID: 21083435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.
    Watanabe SM; Simon V; Durham ND; Kemp BR; Machihara S; Kemal KS; Shi B; Foley B; Li H; Chen BK; Weiser B; Burger H; Anastos K; Chen C; Carter CA
    Retrovirology; 2016 Sep; 13(1):64. PubMed ID: 27600154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals.
    Ngcapu S; Theys K; Libin P; Marconi VC; Sunpath H; Ndung'u T; Gordon ML
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29117130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.
    Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO
    J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
    J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
    Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
    AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
    Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
    Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
    [No Abstract]   [Full Text] [Related]  

  • 33. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
    Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
    Verheyen J; Verhofstede C; Knops E; Vandekerckhove L; Fun A; Brunen D; Dauwe K; Wensing AM; Pfister H; Kaiser R; Nijhuis M
    AIDS; 2010 Mar; 24(5):669-73. PubMed ID: 19926962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.
    Rogo T; DeLong AK; Chan P; Kantor R
    Clin Infect Dis; 2015 May; 60(9):1426-35. PubMed ID: 25637585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.
    Ibe S; Shibata N; Utsumi M; Kaneda T
    Microbiol Immunol; 2003; 47(1):71-9. PubMed ID: 12636256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India.
    Sen S; Tripathy SP; Patil AA; Chimanpure VM; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1303-8. PubMed ID: 17961120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.